bpc-157 human clinical trial osteoarthritis For Knee Pain: Early Reported Outcomes, A report on intra-articular BPC-157 for knee pain described high rates of improvement: ~92% with BPC-157 alone, ~75% when combined with thymosin beta-4, BPC-157 as an Investigational Peptide
Description
10.1016/j.jot.2025.06.003 198 OgawaR.MizunoS.MurphyG
In tests, about 13 percent of people receiving the medication showed evidence of brain swelling, compared to less than 2 percent taking a placebo
If a reaction occurs, its typically within several weeks after the first injection
doi: 10.1161/01.atv.20.6.1595
Nature 473 , 308316 (2011)
Ermutigend fr die Sicherheitsfrage unzureichend fr Wirksamkeitsaussagen
